Suppr超能文献

经动脉化疗栓塞联合计算机断层扫描引导下经皮射频消融治疗特殊部位小肝细胞癌

[Transarterial chemoembolization plus computed tomography-guided percutaneous radiofrequency ablation for small hepatocellular carcinoma in special locations].

作者信息

Guo Yong-jian, Huang Wen-sou, Zhou Bin, Chen Jun-wei, Cai Ming-yue, Qian Jie-sheng, Huang Ming-sheng, Shan Hong, Zhu Kang-shun

机构信息

Department of Radiology, Third Affiliated Hospital, Sun Yat-sen University,Guangzhou 510630, China.

Department of Radiology, Third Affiliated Hospital, Sun Yat-sen University,Guangzhou 510630, China. Email:

出版信息

Zhonghua Yi Xue Za Zhi. 2013 Sep 3;93(33):2627-30.

Abstract

OBJECTIVE

To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) plus computed tomography (CT)-guided percutaneous radiofrequency ablation (RFA) for small hepatocellular carcinoma (HCC) in special locations.

METHODS

From June 2008 to December 2011, a total of 36 patients with small HCC (39 lesions) received TACE plus CT-guided percutaneous RFA at our hospital. The follow-up period was over 6 months. They were divided into 2 groups according to the locations of HCC: special location (located at hepatic subcapsular, portal area, next to large blood vessels or other organs) and non-special location groups. All patients underwent TACE at one month pre-RFA.Follow-up imaging with enhanced computed tomography (CT) or magnetic resonance imaging (MRI) was performed one month after combined treatment to evaluate the complete ablation rate in two groups.If a complete ablation was achieved, enhanced CT or MRI was performed every 1-3 months to evaluate the local tumor progression. The occurrence rate of complications, complete ablation rate, local tumor progression and time to tumor progression (TTP) were compared between two groups.

RESULTS

In the special location group, a total of 24 TACE and 26 ablations were performed in 20 patients with 22 lesions while there were 18 TACE and 17 ablations in 16 patients with 17 lesions in the non-special location group.In the special location group, 12 patients (46.2%) suffered procedure-related complications, including a major complication (n = 1, left ventricular failure) and a minor complication (n = 11) of vascular injury (n = 6), subcapsular hemorrhage (n = 3) and arterial-portal vein fistula (n = 2); whereas only 3 patients (17.6%) suffered a minor complication of subcapsular hemorrhage (n = 1) and arterial-portal vein fistula (n = 2) in the special location group. The occurrence rate of complications was similar between two groups (P = 0.101). The complete ablation rate after one month was 68.2% (15/22) in the special location group and it was significantly higher than that of the non-special location group (100%, P = 0.012).In the special location group, the 6-month, 1-, 2-, 3-year local tumor progression rates were 31.8%, 40.9%, 45.5%, 45.5% versus 0,0,0, 5.9% in the non-special location group respectively. The mean TTP of 14.4 months in the special location group was markedly shorter than that in the non-special location group (31.5 months, P = 0.001).

CONCLUSION

The combined regimen of TACE and percutaneous RFA is both safe and feasible for small HCC in special location. And the rate of local tumor progression is significantly higher than that of non-special location tumor. Postoperative close imaging follow-up is needed for tumor residue or recurrence.

摘要

目的

评估经导管动脉化疗栓塞术(TACE)联合计算机断层扫描(CT)引导下经皮射频消融术(RFA)治疗特殊部位小肝细胞癌(HCC)的疗效及安全性。

方法

2008年6月至2011年12月,我院共36例小HCC患者(39个病灶)接受了TACE联合CT引导下经皮RFA治疗。随访时间超过6个月。根据HCC的位置将患者分为2组:特殊部位组(位于肝包膜下、门静脉区、大血管或其他器官旁)和非特殊部位组。所有患者在RFA前1个月接受TACE治疗。联合治疗1个月后进行增强计算机断层扫描(CT)或磁共振成像(MRI)随访,以评估两组的完全消融率。若实现完全消融,则每1 - 3个月进行增强CT或MRI检查,以评估局部肿瘤进展情况。比较两组并发症发生率、完全消融率、局部肿瘤进展情况及肿瘤进展时间(TTP)。

结果

特殊部位组20例患者22个病灶共进行了24次TACE和26次消融,非特殊部位组16例患者17个病灶共进行了18次TACE和17次消融。特殊部位组12例患者(46.2%)出现与手术相关的并发症,包括1例严重并发症(左心室衰竭)和11例轻微并发症,其中血管损伤6例、包膜下出血3例、动脉门静脉瘘2例;而非特殊部位组仅3例患者(17.6%)出现轻微并发症,包括包膜下出血(1例)和动脉门静脉瘘(2例)。两组并发症发生率相似(P = 0.101)。特殊部位组1个月后的完全消融率为68.2%(15/22),显著高于非特殊部位组(100%,P = 0.012)。特殊部位组6个月、1年、2年、3年的局部肿瘤进展率分别为31.8%、40.9%、45.5%、45.5%,而非特殊部位组分别为0、0、0、5.9%。特殊部位组的平均TTP为14.4个月,明显短于非特殊部位组(31.5个月,P = 0.001)。

结论

TACE与经皮RFA联合方案治疗特殊部位小HCC安全可行。且局部肿瘤进展率显著高于非特殊部位肿瘤。术后需要密切影像学随访以观察肿瘤残留或复发情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验